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Abstract
Background: The immunemodulating drug, inﬂiximab, is
approved for Inﬂammatory Bowel
Disease (IBD) treatment in children.
Chronic therapy with inﬂiximab is
associated with the development of
early and delayed infusion reactions.
We reviewed our experience with
inﬂiximab treatment and its side
effects in a cohort of children
diagnosed with IBD who were treated
in our clinic.
Methods: A retrospective analysis of
all IBD children treated with
inﬂiximab in our center from 20062011 was performed. The
demographic, chronological and
clinical data were recorded. The
inﬁximab infusion was given at 5mg/
kg according to a standard protocol
after pre-treatment with low dose
steroid and diphenhydramine.
Results: Of 30 IBD patients (23
CD/7 UC) receiving 454 infusions (341
CD/113 UC), six (20%) patients
experienced early infusion reactions.
Two (6.7%) patients had a delayed
reaction; of those, both required
intestinal resection.
Conclusion: Our study is the ﬁrst to
address the safety of inﬂiximab
infusion reactions in children in the
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Inflammatory Bowel disease
(IBD) consists of ulcerative colitis
(UC), Crohn’s disease (CD),
or intermediate colitis (IC). An
estimated 1-1.5 million people in the
US have ulcerative colitis or Crohn’s
disease.1 The most common clinical
symptoms of IBD in children include
bloody stools, weight loss, fatigue,
abdominal cramping, increased
frequency of bowel movements,
and fever.2 Crohn’s disease is
histologically characterized by noncaseating granulomas, transmural
inflammation, cobblestonetype mucosa, and bowel wall
thickening.3 The etiology of IBD
is related to a combination of
immune dysregulation and chronic
inflammation, leading to bleeding
of the mucosa.3 TNF-alpha is an
important cytokine central to the
inflammatory process of IBD.
Macrophages, mast cells, and
activated T-helper cells (particularly
TH1 cells) are responsible for
the secretion of TNF-alpha.3
The treatment of IBD is based
on the severity of the disease. For
mild IBD, aminosalicylates and
antibiotics are used.4,5 For more
severe cases, immuno-suppressive
drugs, such as azathioprine or
methotrexate, are utilized. For
refractory cases, the biological
drugs such as anti-TNF-alpha
medications [infliximab (Remicade),
adalimumab (Humira)] or other
investigational drugs may be used.
Infliximab is an anti-TNF-alpha
drug administered by IV for the
treatment of children with moderate/
severe IBD. It is a monoclonal
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anti-TNF IgG molecule composed
of part human and part mousederived TNF-alpha binding regions
(chimeric).6 Infliximab binds to
TNF-alpha with high affinity and
specificity and blocks free TNFalpha in the serum.6 The drug also
affects TNF-alpha molecules that
are attached to target cells such
as the intestinal enterocytes.6
Anti-TNF medications have been
approved for the treatment of IBD
in children. Furthermore, chronic
therapy with these drugs is usually
required and may be associated
with the development of early
or delayed infusion reactions.
In the present study, we reviewed
the early and delayed adverse
events associated with infliximab
infusion in a cohort of IBD children
followed in our medical center.

Material and Methods
A cohort of children diagnosed with
IBD, who were treated with infliximab
at Marshall University Department
of Pediatrics, Gastroenterology
Division, between 2006-2011,
was included in our study.
Demographic, clinical symptoms,
and infusion reaction data were
recorded from the patients’
charts. Per the recommended
clinical guideline, all patients were
screened negative to TB testing
(Mantou test) before initiation
of infliximab therapy. Infliximab
infusion was given per written
standard protocol that included
pre-administration (IV) of low dose
steroid and diphenhydramine. The
recommended dose of infliximab for
pediatric patients 6 years and older
with moderately to severely active
Crohn’s disease or ulcerative colitis
was given as follows: induction dose
of 5 mg/kg given IV at 0, 2, and 6
weeks, followed by maintenance
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Table 1. Common reactions to inﬂiximab infusion.
Early infusion reactions (1-3 days post infusion)
Hypersensitivity reactions and anaphylaxis associated
with facial ﬂushing, shortness of breath, chest tightness,
pruritus, tachy/bradycardia, hives, nausea/vomiting/
diarrhea, seizures

regimen at 5 mg/kg. Patients initially
received the infusion every 8 weeks,
but the frequency was changed
to every 6 weeks according to the
clinical response of the patient.
An early infusion reaction was
deﬁned as either hypersensitivity or
an anaphylactic reaction occurring
during the infusion, immediately
post-infusion, or up to three days
post-infusion. Early infusion
reactions consisted of facial ﬂushing,
fevers and chills, pruritus, heart
rate changes and other symptoms
as outlined in Table 1. A delayed
adverse event was deﬁned as a

Delayed Adverse events (3-12 days post infusion)
Tuberculosis, intra-abdominal abscesses, opportunistic
infections, pseudo-membranous colitis, Hodgkin’s lymphoma,
upper respiratory infections, pharyngitis, neutropenia,
thyroiditis, pancreatitis, seizures, psoriasis, bronchitis,
pneumonia, bacterial infection, abnormal LFTs, appendicitis

reaction that occurred 3-12 days
after the infusion.7 Those events may
include respiratory infections (i.e. TB)
and/or other serious infections (intraabdominal abscesses, opportunistic
infections), pseudo-membranous
colitis, gastroenteritis, thyroiditis,
pancreatitis, seizures, psoriasis,
pneumonia, or appendicitis.7

Results
Thirty patients were included
in the study, of whom 23 had
CD and 7 had UC. A total of 454
infusions were given during the

study period; 341 infusions were
given to the CD patients and 113
were given to the UC patients.
Experimental data and infusion
data are described in Table 2. In
26 of the 454 total infusions, a
total of six patients experienced
early infusion reactions and two
experienced delayed adverse
events. Six IBD patients experienced
early infusion reactions associated
with hypersensitivity (itching, facial
ﬂushing, chest tightness and/or
shortness of breath). All responded
to decreased infusion rate and
completed their therapy uneventfully.
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Table 2. Infliximab infusions and reactions for Crohn’s disease and ulcerative colitis patients.
Crohn’s Disease

Ulcerative Colitis

23 (13/10)

7 (6/1)

Age of patients at conclusion of study (mean)

16.7

16.3

No. infusion (total)

341

113

No. infusion/ pt (Mean + SD)

14.7+ 11

14.1+ 9.5

No. infusion/ pt [Median (range)]

15 (1-35)

11 (3-27)

Early infusion reaction

5

1

Delayed adverse event

2

0

Diagnosis
No. pts (M/F)

A delayed adverse event (intraabdominal abscess) was seen in
2 CD patients; in both cases an
intestinal resection was needed.

Discussion
Anti-biological drugs, such as
infliximab and adalimumab, are
very potent medications for children
with IBD. Results have shown that
since these drugs were approved
for this disease by the Food and
Drug Administration (FDA), the
entire prognosis of IBD patients
has dramatically improved; the
remission rate has increased and
the hospitalization rate and number
of operations have decreased.8,9,10
As with all potent medications,
the side effects of these drugs
are significant, including: immune
suppression, secondary infection
(viral, TB and more), autoimmune
disease (arthritis and psoriasis), and
cancer development (lymphoma and
hepato-splenic T cell lymphoma).7
In addition to these effects, there is
increasing evidence of the reactions
associated with the infusion itself.
In a recent multicenter registry, the
infusion-related side effects were
described in 533 pediatric patients
who had a total of 6914 infusions.11
In that report, 72 (13.5%) patients
experienced early infusion reactions
associated with facial flushing and
shortness of breath. In the same
study, delayed adverse events
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occurred in 38 patients, including 7
(1.3%) with pancreatitis, 13 (2.4%)
with psoriasis, 4 with abnormal
LFT’s, 10 with opportunistic
infections, 1 with neutropenia,
and 2 with seizures.11 One patient
developed Hodgkin’s lymphoma
of the bowel. No intra-abdominal
abscesses were reported. Hyams
et al studied 60 patients receiving
670 infusions, of which 14 patients
(23%) developed early infusion
reactions.7 Delayed adverse
events developed in 46 (77%)
patients, including upper respiratory
infections, pharyngitis, bronchitis
or pneumonia. Severe adverse
events were noted in 20 (33.3%)
patients, which included an intraabdominal abscess, appendicitis,
pneumonia, gastroenteritis,
pseudomembranous colitis, and/
or bacterial infection.7 In our small
cohort, only six (20%) patients
developed early infusion reactions
and two (6.7%) experienced delayed
adverse events (Table 1). The
rate of early infusion reaction was
higher in our study compared to
Markowitz et al (20% vs. 13.5%,
respectively), but the latter study
was a collection of data from a
registry list collected from multiple
clinical centers, while our data was
derived from a single center from
WV. When we compared our data
to a single center report (i.e. the
study from a center in Connecticut),
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our early infusion reaction rate was
lower (20% vs. 33%).7 Additionally,
it has been documented that
approximately 10-30% of patients
suffering from Crohn’s disease
can expect an abdominal or pelvic
abscess to develop spontaneously
during the course of their disease
without ever receiving an infusion
of infliximab.12 Thus, it is possible
that the abscesses reported in our
patients were developed as a result
of the illness itself. Nonetheless,
no patients in our study developed
abscesses before starting the
treatment with infliximab suggesting
that the drug was a major contributor
to the abscess development.
Additionally, the low rate of overall
adverse events (26/454 infusions,
5.7%) noted in our study may
partially be related to the pretreatment infusion of steroid and
diphenhydramine. A pre-medication
regimen was not described in the
previously cited multicenter study,
but other reports have supported this
practice.13,14 In addition, to reduce
complications, it is important to
follow the infusion protocol closely to
include gradual increase/decrease
of the infusion rate followed by a
close monitoring of the patients.
Our pilot study is limited by
the small number of patients and
the retrospective nature of the
investigation. Further research
could include a multi-center study in
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the state. Nevertheless, our study
demonstrated encouraging results
that lend support to the safety of
infliximab in children diagnosed with
IBD. Our data support the notion
that infliximab treatment for children
in WV is safe and feasible. To our
knowledge, this is the first report of
infliximab infusion adverse events
in children from West Virginia.
In conclusion, we find the
infusion of infliximab to be safe in
children with moderate to severe
IBD, particularly when preventive
measures are taken to minimize
or stop the progression of infusion
reactions. Our data suggest that
our patient population should not
seek out-of-state medical services
for intravenous infliximab therapy,
and that such therapy is available at
various GI centers within the state.
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